Method of producing derivatives of 4-benzyl-1(2h)-phthalazinone or physiologically endured acid-addi

专利摘要:
The invention relates to heterocyclic compounds, in particular, to the preparation of 4-b nssh1-1 (2H) phthalazinone derivatives of the formula CH CH-CH (O) -NA-N CC H R D, where RF, C1, Br, C-C alkyl H or C1, and A is the residue. O-rs. the RJ-C, -C-apkyl group, which is substituted by the following residues: a) a phenyl residue or a phenylcarbonyl residue, which may respectively also contain 1,2 or 3 identical substituents, the latter being halogen atoms, trifluoromethyl, C -Cd-alkyl groups or C, -Cz-alkoxy groups, or c) -alkoxy or hydroxy-C-C - -alkoxy, or c) kiloamino, or d) Cj-C-cycloalkyl residue or Cj-C - a cycloalkylcarbonyl residue, or R is a singly unsaturated C-C-alkyl group, is not substituted once Cj-C is an alkyl group with a phenyl residue or a C3-C alkyl alkyl carbonyl group with a phenyl residue, or their physiologically tolerable acid addition salts, except for compounds where A is CH — CH-CHj-CHj-NRj- - CH, - CH, RJ - allyl, benzyl, phenethyl, or their physiologically tolerated acid additive salts exhibiting antiallergic, histaminolytic and asthma-prophylactic activity. The goal is to develop a method for obtaining new more active compounds. Their preparation is carried out from the corresponding compounds, where RJ-H, and compounds of the formula R3X, where Rj is as indicated above, and X is an esterified hydroxy group with a strong inorganic or organic acid. The desired product is isolated in free form or in the form of a physiologically tolerable acid addition salt. . 5 tab. i CO 1 you ate cm
公开号:SU1454251A3
申请号:SU864028445
申请日:1986-11-06
公开日:1989-01-23
发明作者:Энгель Юрген；Шеффлер Герхард
申请人:Аста-Верке Аг,Хемише Фабрик (Фирма)；
IPC主号:

专利说明:

This invention relates to a process for the preparation of A-benz 1-1 - (2H) -phthalazinol derivatives. The compounds of the invention have antiallergic, histaminolytic and asthma-prophylactic action, therefore they can be used in medicine.
The purpose of the invention is to obtain 4-benzyl - 1 - (2H) -phthalazinone derivatives. possessing a significantly greater physiological effect as compared with compounds of similar structure.
Example 1. 4- (p-Chlorobenzsh1) -2-hexahydro-1- (p-methylbenzl) -azapin-4-yl -1- (2H) -phthalazinone
€ 1
ABOUT
0.016 mol (7 g) of 4- (zyl) -2-Xhexahydroazepin-4-yl) -1- - (2H) phthalazinone-1bromide a is dissolved in 50 ml of dioxane at 50 ° C. Under stirring, 0.048 mol (6,, 5 ml or 3; 7 t) of triethylamine and 0.016 mol (2.1 or 2.2 g) of 4-methylbenzyl chloride are added to this solution. After that, it is stirred for 5 hours at 85 ° C. It is left to cool to room temperature, the mixture is filtered and the resulting solution is concentrated on a rotary evaporator. The dark oily residue is dissolved in a saline solution (shots in propanol and precipitated by adding simple ether to the oil-oily product. The protruding solution is settled. The residue oil is covered with a layer of ether and left overnight in a closed flask at room temperature. After This is triturated with a little hardened substance with parts of ether, sucked off on a putch and dried in air. In conclusion, dissolved in warm methyltstilketone, ether is added until cloudy and the salt is left overnight to crystallize. Filtered product was dried in vacuo. "Yield 3.4 g (43%). mp. 191-1 (hydrochloride chloride).
The starting material is prepared, for example, as follows. 60 g (Oe157 mol) 4- (p-chlorobenzyl) -2- - (hexahydro-1-methyl azepin-4-yl) -1- (2H) phthalazino is dissolved when heated to 95 ° C in 600 ml of dry toluene . Then, 51.1 g (0.471 mol-15 ml) of ethyl chloroformate in 45 ml of toluene are instilled in with stirring. The mixture is stirred for 5 hours at. After cooling to room temperature, the reaction mixture is sucked off on a coup from the insoluble part and ends of the ripples on a rotary apparatus. An oily residue remains, which, after grinding with a small amount of ether, is obtained as a white crystalline product, having a melted point of 103-105 ° C.
Output
53.4
g (77%)
53.4 g (0.12 mol) of TachS obtained by 1-carbztoxy derivative (formula (I), in the remainder AR — COOC H) and 114 ml of 40% aqueous solution of hydrogen bromide in glacial acetic acid are heated with vigorous stirring 4 h to 85-90 s, with increasing heating of the carbethoxy compound goes into solution. After cooling, the solution is concentrated in vacuo. From the viscous viscous (oily residue is obtained by recrystallization from methanol, the starting compound of formula (I), where Rj is hydrogen, is in the form of white crystalline hydrobromide.
Suction is performed under suction, repeated rinsing with methanol and drying in vacuum. Vcode 51 g (95%). M.p. 138-140 C.
To obtain the free base, the hydrobromide is suspended in 300 ml of distilled water and the alkaline reaction is established using 100 ml of concentrated ammonia. After stirring for 2 hours, suction is performed on suction and rinsing with water until the washing solution is neutral. The white product is dried in a vacuum extractor for several days. Yield 125 g (77% of theory). M.p. 123-125 ° C.
Calculated,%; C 68.50; H, 6.16; N, 8.26.
gHj, (502, 505).
Found,%: C 68.60, H 6.30, N 8.30.
Analogously to Example 1, compounds of formula (I) are obtained, which are listed in Table 1. Unless otherwise indicated, the melting points of the corresponding hydrochlorides are listed in column 4. In examples 2-8, the molar amounts of the starting compounds (II) and (III), respectively, are the same, in examples 9-11 and 13 are introduced
respectively 0.027 mol in the example 12–0.015 mol of the starting compound (II). In examples 6-11 and 13, the starting compound is introduced in the form of a free base, in examples 1-4 and 12, as hydrobromide.
The processing of the reaction product after concentration or removal of the reaction solution occurs in examples 6, 7, 10 and 13 as in example 1.
In examples 2 and B, the residue obtained after evaporation of the reaction mixture (after its crystallization) is recrystallized from isopropanol before the salt formation with the aid of a solution of HCl in isopropanol, in example 3 from methanol and in example 5 from ethanol.
In examples 4, 9, 11 and 12, the residue from evaporation of the reaction mixture (if necessary, after grinding 10 examples 2-4 and 9-13, is 4- (p-chloro-benzyl) -2- (he sahydroazepin-4, respectively) -yl) -1- (2H) -phthalazinone. Starting compound (II) (4-p-fluorobenzyl) -2- (hexahydro-ase
15 pin-4-yl) -1- (2H) -phthalazinone for
Examples 5-8 can be obtained, for example, in the following way.
50 g (0.136 mol) of well-dried 4- (fluorobenzyl) -2- (hexahydro20 -1-methyl azepin-4-yl) -1- (2H) -phthalazinone are dissolved in 400 ml of toluene by heating to. If droplets are deposited on the inner wall of the shell, this residual water will be removed
25 using a water separator by azeotropic distillation. Then 44.5 g (0.408 mol 38 ml) of ethyl chloroformic acid are instilled.
additionally stirred for 1.5 hours. After cooling to room temperature, the product is sucked off on the suction of insoluble components and the resulting solution is concentrated under vacuum.
thirty
The remaining syrup that the cris itself is
neither with isopropanol and ether) 35 was Talisin, triturated with a simple
54251
using a solution of HCl in isopropanol or methyl ethyl ketone and precipitating the salt with ether (Example 13). Then, the resulting salts can also be recrystallized from a suitable solvent (for example, isopropanol).
 The original compound (II) for
10 examples 2-4 and 9-13 are respectively 4- (p-chloro-benzyl) -2- (hexa-hydro-azepin-4-yl) -1- (2H) -phthalazinone. The starting compound (II) (4-p-fluorobenzyl) -2- (hexahydro-aze15 pin-4-yl) -1- (2H) -phthalazinone for
Examples 5-8 can be obtained, for example, in the following way.
50 g (0.136 mol) of well-dried 4- (fluorobenzyl) -2- (hexahydro20 -1-methyl azepin-4-yl) -1- (2H) -phthalazinone is dissolved in 400 ml of toluene by heating to. If water droplets are deposited on the inner wall of the flask, this residual water is removed at
25 using a water separator by azeotropic distillation. Then, 44.5 g (0.408 mol 38 ml) of ethyl chloroformate and
additionally stirred for 1.5 hours. After cooling to room temperature, the product is filtered off with suction from insoluble components and the resulting solution is concentrated in vacuo.
thirty
The remaining syrup that the cris itself is
it is first purified on a silica gel column, and then after removing the solvent with an HCl solution in isopropanol, the hydrochloride is obtained. The solvent is dichloromethane: methanol: ammonia 25% 85: 15: 1.
In the case of Example 12, after the chromatographic purification, the base is also dissolved in acetone and oxalate is obtained by addition of anhydrous oxalic acid dissolved in acetone; in the case of Example 9, the residue after chromatography is not converted to salt.
In order to obtain salts in crystalline form, if necessary, it is advisable to re-triturate with ether or also methyl ethyl ketone, it is sometimes recommended to also release the base with concentrated ammonia, extract-shake with ether, dry and re-saltform.
five
ether. Belsh crystalline product is sucked off under suction, washed with ether and dried. Yield 33 g (57%). M.p. 95-964.
A mixture of 33 g (0.078 mol) of the compound thus obtained and 65 ml of 40% HBg (glacial acetic acid) is slowly heated to an oil bath temperature of 100 ° C and stirred for 2 hours. The mixture is cooled and the solution is concentrated on a rotary evaporator. The oily residue is dissolved in 250 ml distilled and the solution is adjusted to an alkaline reaction by adding 40 ml of concentrated ammonia. Then the base is precipitated as a crystalline precipitate, it is suctioned off with suction and dried in a desiccator over semi-5- phosphorus oxide. Yield 23 g (48%).
M.p. 86-88 ° C .;
4- (Fluorobenzyl) -2-hexahydro-1- -metsch1-azepin-4-yl) -1- (2H) -phthalase0
non receive, for example, as follows.
230 g (0.809 mol) of N 6eH30Hn-N - - (1-methyl-hexahydroazepin-4-yl) - hydrazine is heated for 4 hours with 830 ml of 23% hydrochloric acid under reflux (benzoic acid precipitates). Cool and concentrate on a rotary apparatus, add about 200 ml of toluene and concentrate again. The residue is boiled with 209 g of 2- (4-fluoro-phenacetyl) benzoic acid, 149.5 g of 85% KOH and 2300 ml of methanol for 2.5 hours. Concentrate the mixture and stir the residue with 3.3 and 785 ml 2 molar NaOH. The base precipitates. Blend: sew in addition, suck on suction and rinse until neutral. Dried under vacuum.
3Q,
one
Examples 14-43 (table 2 and 3).
Compounds (I) according to examples 14-38 were prepared as follows.
25 moles of dioxane, 3 moles of triethylamine and 2 moles of starting compound (III) are added at room temperature to 1 mole of the starting compound (II) 25 tats (free base), the reaction mixture is heated for several hours at 100 ° C and drunk after concentration into distilled water. Further processing takes place according to method A or B.
Method A. Water-insoluble May-35 is extracted 2 times with ether, the combined ether extracts are washed once with water and dried over Na 80+,
After evaporation, the remaining little is taken up in a mixture of isobutyl methyl ketone (or ethyl methyl ketone) toluene, acidified with a solution of hydrochloric acid in isopropanol and, if necessary, concentrated slightly. After infection of the hot solution, the crystals obtained in the tube (and / or the addition of ether) give a crystalline product.
Method B. The insoluble in water and maize are extracted 3 times with methylene chloride, and the combined organic phases are washed 2 times with water. Dried
The scientific research institutes, for examples 25-43, use the initial compound (II), where R represents a fluorine atom in the p-position. In Table 2, A always represents
Is he,.
Table 3 always has a residue
o The starting materials of the formula (II for examples 14-43 are chlorides of the formula Cl-Rj, and Rj has the values listed in Table 2 or Table 3 column 2.
The letter Z after the melting point means that the corresponding substances melt with decomposition.
The products of the method according to examples 16, 19, 22, 24, 31 and 33 of table 2 and according to example 37 of table 3 each contains 1 molecule of water of crystallization.
The preparation of compounds (I) according to 45 examples 39-43 is carried out (Table 3 according to the following working instructions (the reaction temperature and amount of solvent are indicated here in the last column of Table 3).
0.05 mol of the starting compound (II) (free base) is introduced into the solvent and dissolved at 40-50 with stirring. Proton trap is added (or
above the solution is concentrated on a rotary vat apparatus, the residue is dipped-55 triethylamine) and the original is instilled with 50-70 ml of acetone and stirring the compound (III) (Cl-Rj). React with 20 g of silica gel (serves to adsorb the starting substance). After stirring for 10 minutes, the suction mixture is boiled for several hours under reflux and stirred at a certain temperature. After cooling
4542516
from silica gel to concentrate the filtrate. The residue from evaporation is taken up with methyl ethyl ketone / toluene, acidified with a solution of HCl in isopropanol, and the solution is concentrated to O-. thawing cloud. If necessary, the addition of ether contributes to crystallization. The resulting crude product is suction filtered under suction, washed with acetone and evaporated with CHtCl / methyl ketone. After hours of suction, the product is sucked off with suction, washed with a large amount of acetone and diethyl ether, and the crystals are dried under vacuum.
For examples 14-24, the starting compound of formula (II) is used, wherein
20 Rf is a chlorine atom in the p-bed
The scientific research institutes, for examples 25-43, use the starting compound (II), where R represents a fluorine atom in the p-position. In Table 2, A always represents
oso,
3Q,
one
25 tats
Table 3 always
tatok
The starting materials of formula (III) for examples 14-43 are chlorides of the formula Cl-Rj, and Rj has the values listed in Table 2 or Table 3 in column 2.
The letter Z after the melting point means that the corresponding substance melts with decomposition.
The products of the method according to examples 16, 19, 22, 24, 31 and 33 of table 2 and example 37 table 3 contain 1 molecule of water of crystallization.
The preparation of compounds (I) according to examples 39-43 is carried out (Table 3) according to the following working instructions (the reaction temperature and the amount of solvent are indicated here in the last column of Table 3).
0.05 mol of the starting compound (II) (free base) is introduced into the solvent and dissolved at 40-50 ° C with stirring. Proton trap is added (or
triethylamine) and the starting compound (III) is instilled (Cl-Rj). The reaction
triethylamine) and the starting compound (III) is instilled (Cl-Rj). The reaction
The mixture is refluxed for several hours under reflux and stirred at a certain temperature. After cooling to room temperature, the precipitated salts are filtered off with suction and the filtrate is concentrated on a rotary evaporator. (The process is processed and the product formed is purified by recrystallization or column chromatography. Salt formation is used to improve solubility. In order to obtain hydrochloride, the base is suspended in ethyl methyl ketone or isopropanol, mixed with a solution of HCl in isopropanol to obtain an acid layer and placed in a solution and placed with a soft wall with a HCI solution and isopropanol to be treated with a solution. ethyl ether before the first slight turbidity. Corresponding oxalate is obtained by dissolving the substance in acetone and adding anhydrous also dissolved in acetone. th oxalic acid.
In examples 39-41 and 43, dioxane is used as a solvent and as the main compound three30.
35
ethylamine (in example 43: 0.15 mol tri-25 ethylamine, otherwise 0.1 mol).
In example 42, dimethylacetamide is used as a solvent and 0.1 mol of KjCOj as the main compound. The amount of the starting compound (III) Rj-Cl in examples 39-41 is 0.06 mol, in examples 42 and 43, respectively, 0 1 mole
Recycling. In Examples 39-41, the residue after coagulation of the reaction mixture is recrystallized from ethanol (50-250 ml) with the addition of coal (in Example 41 with the addition of infusor i earth) and then hydrochloride is obtained.
In examples 42 and 43, the oily residue is triturated with 50 ml of diethyl ether, respectively, crystallization occurs, and chromatography is added in example 43. phi on a column of silica gel (solvent: dichloromethane / methanol / ammonia 25% 85/51/1).
In examples 14-43, Rj is always hydrogen.
Examples 44-48. The compounds of formula (I) in the 4th position, A, table. 4) receive according to examples 44-48 according to the following working instructions.
0.011 moles of the Precursor (II). (Free base) - injected in 50 ml of dioxane (30 ml of dioxane in Example 48, 25 ml of dioxane in Example 49)
ten
15
20
50
55
40
45
and dissolved at 40–50 ° C with trans
stirring. 0.033 mol of triethylamine (0.0133 mol in example 49) is added, and the starting compound (III) (C1 - Rj) is added dropwise, the reaction mixture is boiled for several hours under reflux or stirred at a certain temperature. After cooling to room temperature, the precipitated salts are precipitated on suction and
concentrate the filtrate on a rotary evaporator. The residue is processed and the product formed is purified by recrystallization (Examples 44,
 5 45, 47 and 48) or by column chromatography (Example 50). Solvent: dichloromethane / methanol / ammonia 25% 85/15/1. In most cases, salt formation is added to improve solubility. To prepare the hydrochloride, the base is suspended in ethyl methyl ketone or isopropanol, mixed with a solution of HCl in isopropanol until acidic, and placed with diethyl ether until the first slight turbidity.
Example 51. 4- (3,4-Dichlorobenzyl) -2- (hexahydro-1-benz 1-aze-PIN-4-IL) -1- (2H) -phthalazinon
SNG
N.
k ji i - i -cHj-CeHs
ABOUT
A solution of 3.28 g (8, 15 mmol) of 4- (3,4-dichlorobenzyl) -2- (hexahydro-1H-aze pin-4-yl) -1- (2H) -phthalazinone, 3.4 ml ( 29.5 miol) benzyl chloride and 9 ml (64.6 mmol) of triethylamine in 20 ml of dioxane are heated for 12 hours at 200 C.
After that, it is concentrated, the residue is mixed with water and the mixture is extracted by shaking dichloromethane. The organic phase is dried with MgSO4, filtered and concentrated. The remaining oil crystallizes overnight. The crystals are suspended in ether and stirred. After suction on the suction and washing the substance with ether, the solution is rotated.
A colorless crystalline substance is obtained with a mp, D 7-118 ° C, Yield ,,, 55 g (14%).
Calculated,%: C 68.29, H 5.53, N 8.53 ..
.CljNjO (429, 446),
Found: C, 67.90; H, 5.50; N8.40.
Example 52 4- (3,4-Dichlorobenzyl) -2- (hexahydro-1-phenethyl-α-azepin-4-yl) -1- (2H) -ft azinone „
3.36 g (8.35. Mmg) 4 (3,4-Dichlorobenzyl) -2- (hexatidro-1H-aeepin-4-yl) -1- (2H) -phthalonone 4 ml (29, 3 mmol) of phenethyl bromide and 4 „5. Br (32.20 mmol) of trietaminamine are dissolved in 20 ml of dioxane. The reaction mixture is stirred for 2 hours at
It is evaporated, the residue is mixed with water, extracted with dichloromethane, dried with MgSO4, filtered, concentrated and the resulting oil is chromatographed on a column of silica gel. The base obtained from the corresponding eluates is converted to oxalate,
Vigeod 0.39 g (about 8%). M.p. 161-192 ° C.
Calculated,%: C 62.42, H 5.24, 7.04.
Sz, H. (596, 513)
Found%: C 61.20, H 5.27, N 6.70,
Example 53 4- (4-Meter-Shben zil) -2- (hexahydro-1 benzyl azepine-) - 1- (2H) -phthalazinon
N
- (- sn-SvNz
II
ABOUT
3.02 g (8.69 mmol) 4- (4-Methylbenzsh1) -2- (hexahydro-1P-azepin-4-yl) -1-1 (2H) -phthalazinone, 3 ml (26.00 mmol benzyl: chloride and 3.6 ml (25.8 mol) of trietclamine are dissolved in 20 ml of dioxane. The reaction mixture is heated for 10 hours with stirring at 100 C. After that, it is concentrated and the residue is mixed with water and extracted with dichloromethane. The solution is dried with MgSO4, filtered and sgu
schakgt The oily residue is chromatographed on a column of silica gel.
After concentration of the eluate, a crystalline product is obtained, which is suspended in ether, triturated and sucked off under suction.
Yield 1 g (26.3%). M.p. 128-129 C.
Calculated,%: C 79.60, H 7.14; 9.60.
C, jgH ,,. (437, 583) Found,%: C 78.59, H 7.22 7.79.
Example 54. 4- (4-Fluoro-benzyl) -2-1- (3- (35, 4,5-trimethoxy-phenyl-car-6-propyl- (1) -hexahydroazepin--1- (2H) phthalazin-Hs
-f
ShgPg
chDum - (- SNG-SN4-SN ,, - OS
at
about
OCHj OCHg
ecKs
in apparatus with a stirrer, 120 ml of dried dioxane, 11.7 g (0.033 mol) of 4- (4-fluoro-6enzyl) -2- (hexahydro-az epin-4-yl) -1- (2H) -pha- lasinone, 13.7 kp (, 033 mol) of triethylamine and 12.4 g (1.30.033 mol) of 3- (3.4 S 5-trimethoxy-phenylcarbonyl) - propyl chloride. 15 h with phlegm. The dioxane is then distilled off in a rotary evaporator, the residue is stirred with methylene chloride. The solution thus obtained is extracted with water, the solution of methylene chloride in a rotary evaporator is evaporated and the residue is purified on a column of silica gel.
The product thus obtained is dissolved in ether and the hydrochloride is precipitated with HC1. After recrystallization with 30 ml of isopropanol, the hydrochloride has a mp. 1455
148
N
N
C (yield 4.2 g). Calculated,%: C 65.43j H 6.30, 6.73.
 gClFNjOs (624, 167). Found,%: C 65.20, H 6.40; 6.90.
Example 55. 4- (Fluoro-benzyl) - (3-trifluoromethyl-phenyl-ethyl) - -hexahydroazepin-4-yl -1- (2H) -taf-lasinonl-l
CH, -F
SGS
-CH, Hf
/
to
To 80 ml of dioxane was added 10.5 g (0.03 mol) of 4- (4-fluoro-benzyl) -2- (hexahydroazepin-4-yl) -1- (2H) -tafazinone, 9 , 1 g of triethylamine and 5 ka-pepl of dimethylformamide, instilled into the mixture at room temperature 10 g (0.04 mol) of 2- (3-trifluoromethylphenyl) ethyl bromide and heat for 6 hours under reflux. After cooling, the aspirated 10 are suctioned. The solution is concentrated in a rotary vane apparatus and dissolved in 150 ml of CHClg and extracted 2 times, each time with 50 ml, the CHCl j phase is dried over MgSO4, filtered off and concentrated. The residue is triturated with ether, left overnight, sucked off, further washed with ether and dried in vacuo at 40 ° C. In isopropanol using hydrochloric acid in ether, the hydrochloride is obtained and recrystallized from a 40-fold amount acetone. Hydrochloride has so pl. 184-25 187®С (yield 6.1 g).
Calculated,%: C 64.34; H 5.40; N 7.50.
CjoH OK3ClF4 (560.03)
Found,%: C 64.30 H 5,
N 7.20.
Example 56. N-benzoyl-H - - (N-metsh1-piperidin-4-yl) -hydrazine.
In 1500 ml of methanol, 272 g (2 mol) of benzoic acid hydrazide 35 are introduced with stirring. Then for one hour, instilled at 226 g (2 mol) of 1-methyl-4-piperidine. Slight cooling is necessary. The reaction mixture was additionally stirred for half an hour at 30 ° C and then for another 1 hour at 60 ° C. The solution is cooled before and 68 g (1j8 mol) of NaBH4 (strong foaming) are introduced with a spatula within 2 hours. By the end of the addition, the mixture is heated to room temperature. The solvent is evaporated on a rotary evaporator and 900 g of ice and 1000 ml of dichloromethane are added to the residue and stirred. The organic phase 50 is separated in a separatory funnel and the aqueous phase is extracted by shaking 2 more: 2 times, each time with 300 ml of dichloromethane. The collected organic fractions were dried over MgSO 5. 55 Dichloromethane was evaporated and the residue was recrystallized from 1 L of isopropanol with the addition of 10 g of active carbon. The reaction product is dried in the drying
cabinet under vacuum (Mp 149-150 ° C).
Example 57. 4-Hydrazino-N- -methylpiperidine “2 HCl.
700 ml of 37% HCl (8.4 mol) are added to 400 ml of water, 233 g (1 mol) of N-benzocl-N - (N-m-I-piperidin-4-yl) - hydrazine and the reaction mixture is boiled for 2 hours under reflux. The benzoic acid released is crystallized in an ice bath and sucked off. The filtrate is evaporated on a rotary evaporator. To remove the possible available water, 250 ml of methanol are added and again evaporated. By stirring the fatty substance in 300 ml of methanol, a crystalline product is obtained, which is filtered off with suction, washed with methanol and dried in vacuo at (Tp,)
Example 58. 2- (4-Fluorofenacetyl) -benzoic acid.
410 ml of 29% NaOH are taken and, at an oil bath temperature (70 ° C), 250 g (1.04 mol) of 4-fluorobenzylidenephthalide are introduced with stirring. By the end of the additive, raise the temperature of the oil bath to. A red oil is formed during the reaction. After 3 h, cool, mix with 500 m of ice water and 340 ml of concentrated HC1 are added dropwise. In this case, rose-colored crystals are precipitated. The latter are aspirated on suction and washed with ice water to remove chlorine. After drying at 50 ° C, it is recrystallized from 900 ml of toluene (mp 147-150 ° C).
Example 59. 4- (4-Fluoro-benzyl) -2-K (-methyl-piperidin-4-yl) -1- - (2H) -phthalazinone.
112.3 g of 85% KOH (1.7 mol) are dissolved in 1890 ml of methanol with stirring. 214 g (0.945 mol) of 4-hydrazino-M-methyl-piperidine 2CH1 are added. and loose the ground. After the addition of 244 g (0.945 mol) of 2- (4-fluoropheneacetyl) -benzoic acid, crystallized KCl is crystallized out. The mixture is refluxed for 4 hours (in the case of other hydrazine compounds and / or phenacetyl benzoic acids). It lasts longer, for example, up to 20 hours. After cooling, the KC1 is separated and the solution is concentrated on a rotary evaporator. 1000 ml are added.
ice water and 928 ml of kaon (2-mol ry) and mix. The N-methyl compound is precipitated and sucked off under suction, washed with ice water and dried.
five
ten
on. The mixture was boiled for 3 hours under reflux and the resulting water was distilled off by azeotropic distillation. The resulting product crystallizes out overnight. The remaining solvent was evaporated and the resulting N-acetyl- (3-H-methyl-8-azabicyclo (Pc2, 1) octane) -hydrazone was recrystallized from 400 ml of ethyl ethyl acetate
in an oven at 50 ° C in a vacuum 5e; (T. pl. 140-143 C).
i Example 60. 4- (4-Fluorobenzyl) I -2- (N-carbethoxy-piperidine 4-yl) -1 - I (2H) -phthalazinone.
366.5 g (1.043 mol) 4- (4-Fluoro-6-xyl) -2 - (H-metshshieridin 4-yl) -1 -
- (2H) -phthalazinone dissolved in 1100 ml
dried over toluene, More
the possible possible zod is disposed of in the autoclave for shaking 15 and set I by azeotropic distillation through a water-pressure of hydrogen of about 5.7 bar. Hydroacids (Tspl. 155-157 0.
58 g (mol) of this compound, 440 ml of glacial acetic acid and 5.8 g of PtO, (81.05%) are then placed
divider. 390 g (3.59 mol) of ethyl chloroformate are instilled within 1j 5 hours and stirred for 4 hours under reflux. A precipitate is formed, which is sucked off with suction, the filtrate is evaporated on a rotary evaporator, the residue is suspended in 400 MP of ether, stirred and sucked off with suction. After 25 simple stains: the substance is dried in a drying oven (T, pl. 151-.
20
).
When im 61 about 4- (4-Fluorobenzyl) - -2 (piperidin-4-yl) -1- (2H) -phthalazinone.
181, 5 g of 48% HBr (1.077 mol) are taken and 110.2 g (0.269 mol) of the N-carbethoxy-piperidine derivative are introduced with stirring. Take it. The residue is dried in an oven
at 50 ° C in vacuum. The 3-hydrazino-b -methyl-8-azabicyclo (3.2.1) octane xHC1 obtained in this way has m, pl. 250 ° C with decomposition.
glacial acetic acid is dripped until a clear solution appears and is heated to the temperature of a small bath (100 ° C). After 9 hours, the solvent was evaporated, 860 ml of water was added to the remaining viscous mass and stirred, and then a white substance crystallized out. With the addition of 138 MJi; concentrated ammonia
the reaction product is precipitated as a base with a length of 30-60 cm, which is started, sucked off under suction, washed
After the Iteoeaecal valve, it is transferred with water and dried in a drying cabinet when the small intestine passes into the thick (Т, pl. 157-159 ° С) lump.
Baseline hydrazino compounds with Guinea Pigs, bisexual with weight A, representing group I-50 400-600 g stun with a blow to the back of the head
Tyla can be obtained, for example, as follows.
Example 62. H-Gidrazino-N- -meth; -8-azabicyclo (3.2.1) octane hydrochloride.
Into 120 ml of toluene, 41.0 g (0.295 mol) of tropine (N-methyl-B-azabicyclo (3,2,1) octan-3-one) and then 22.8 g (0.31 mol) of acetylgium are introduced. , CRSA-
on. The mixture was boiled for 3 hours under reflux and the resulting water was distilled off by azeotropic distillation. The resulting product crystallizes out overnight. The remaining solvent was evaporated and the resulting N-acetyl- (3-H-methyl-8-azabicyclo (Pc2, 1) octane) -hydrazone was recrystallized from 400 ml of ethyl ethyl acetate
acids (Tspl. 155-157 0.
58 g (mol) of this compound, 440 ml of glacial acetic acid and 5.8 g of PtO, (81.05%) are then placed
The reaction is carried out at room temperature. After about 4 hours, H uptake is complete. The catalyst is filtered off and the filtrate is concentrated on a rotary vysarnom apparatus. The N-acetyl-hydrazine compound remains as an oily residue.
1200 ml of 22% HC1 are added to 170.5 g of the oily residue thus obtained. The mixture is heated under nitrogen atmosphere for 8 hours under reflux. The resulting solution is evaporated on a rotary evaporator, and a crystalline substance remains. To remove any water that is still possible, it is mixed 2 times, each time with 150 cells of methanol, and again evaporated. The residue is dried in an oven
at 50 ° C in vacuum. The 3-hydrazino-b -methyl-8-azabicyclo (3.2.1) octane xHC1 obtained in this way has m, pl. 250 ° C with decomposition.
Leukotriene-C4 spasmus in the isolated ileum of the guinea pig (ileum - this is the middle part of the small intestine, namely the small intestine is exsanguinated. The ileum is dissected, rinsed with cold fever and incubated for 1 hour in the refrigerator. 55 of this, a piece 3-4 cm long is cut off from the ileum and suspended into the body of a bath with a thyrod solution (the thyrotic solution is a standard glucose-containing physiological
151
nutrient solution with the same osmotic pressure as blood) with a carbogen treatment (carbogen is a gas mixture consisting of 95% oxygen and 5% carbon dioxide): when pre-fed, in an amount of 2 g - on the rtag). In the first pass, leukotriene C4 is cumulatively injected into the bath solution (1, 1.84 x 10 g / ml bath volume) and millimeters of the height of the spasmus are determined. Then it is thoroughly washed and after 1 hour a test substance is injected in a standard dosage of 10 Mg / ml into the bath solution. After a period of equilibration, a cumulative delivery of C4 leukotriene is carried out for 30 minutes. The percent inhibition of the spasmus in the presence of a test substance is determined in relation to the base value of the first curve characterizing the dose effect for a concentration of 1.84 - 10 g / ml leukotriene. The number of test preparations is 3-8 pieces of organ. The bioassays of the compounds of formula (I) are listed in Table 5.
Azelastine structural formula
C1
The compounds of the invention have low toxicity. The resulting compounds are more active than the known compounds of this series. In addition, in contrast to the well-known medicinal active substance, azelastine has no bitter taste or a significantly less bitter taste, therefore their aerosol application is possible.

权利要求:
Claims (1)
[1]
1.g gtlp11
About
207-211
29
EE
CSNg) h
19S-19E
36- (CHl) 3 .- (3-F
DOS,
37- (cis) s-o-axis5
 OCHj
W (CH,)
39-SJ |
"about ; -CH -cH-CH
41 CSNG191-195
172-176
191-195
219-221
62
64
53
13
63
H 8.52.
C ,, H, jClN, 0 (493.05) Wet, s, Z: C 69.9; H 6.50; And 7.60.
In Calculated, x; C 68, t6; in 6.11 | And 8.22.
Ct, H ,, Cl, F, KjO (511.0) Found, Z: C 68.20; At 6.00; N 8,10.
B Calculated, Z: C 64.00; B 6.71; K 7.00.
C „H“ S1ГЯ, 04 (601.05) Found, Z. С 64.50; B 6.50; H 6.70.
B Calculated, Zt C 68.43; I 6.34;
N 8.25.
Teiperatu - C jHjjClFNjOt (509.05) p «reazhts, Weideno, Z: C 67.64; B 6.24; With / kolneche- N 8,17. solvent 3 120 / 85-90 Calculated, Z: C 69.98; H 5.87; H 9.06.
С, 1Н „С1РН, 0 (463.99) Waideno, Z: С 69.65; H 6.10; L 8.95.
157-158 57 3 120/70 Calc., Z: C, 66.74; B 6.09;
at 10.15.
CijHjsClFKjO (413,946) Weideno, Z: C 65.65; B 6.20; K 10.00.
246-248 59 8 120/101 Calculated, Z C 70.36; H
H 8.79.
C ,, Bj, (478.01) Vaideio, Z: C 69.50; At 6.00; i And 8.20.
p11
24
Continued not table. 2 7
Calculated; Z: C 68.76; B 6.16;
I am 8.02.
Cj.Hj, ClF5N, 0 (524.06)
Found, Z: С BE.ZO; R 6.10;
N 7.80.
Vychksleko, Z: C 64.26; H 5.95; And 7.75.
C ,, H ,, ClFiU, 0 (524.06) RaftncHo, Z: C 65.70; H 5.80; H 7.80.
Tv-lktsa 3
62
64
13
63
Table 5
Table 4
Continuation of table.5
27
1454251
28 Continuation of table. five

类似技术:

---

公开号 | 公开日 | 专利标题

---

SU1454251A3|1989-01-23|Method of producing derivatives of 4-benzyl-1|-phthalazinone or physiologically endured acid-additive salts thereof

---

US4059621A|1977-11-22|Substituted benzamido propanolamines

---

JPH0798819B2|1995-10-25|Substituted bridged diazabicycloalkylquinolone carboxylic acid

---

US4668786A|1987-05-26|P-fluorobenzoyl-piperidino alkyl theophylline derivatives

---

EP0124476A1|1984-11-07|Carboxamides, process for their preparation and pharmaceutical preparations containing them

---

FR2510115A1|1983-01-28|ERGOLINE DERIVATIVES, PROCESS FOR PREPARING THEM AND THEIR USE AS A MEDICINAL PRODUCT

---

US3705907A|1972-12-12|4-|-3-aminopropoxy)-indole derivatives

---

US4678802A|1987-07-07|1-acylcarbamoyloxindole-3-carboxamides as antiinflammatory agents

---

US4528393A|1985-07-09|Derivatives having expectorant activity, the procedure for their preparation and the pharmaceutical compositions which contain them

---

FR2472574A1|1981-07-03|CEPHALOSPORINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION CONTAINING SAME

---

FI83773B|1991-05-15|FOERFARANDE FOER FRAMSTAELLNING AV TERAPEUTISKT ANVAENDBARA 1,4-DIHYDROPYRIDINDERIVAT.

---

US4478837A|1984-10-23|3-Hydrazino cycloalkyl[c]pyridazines as antihypertensive agents

---

DK150071B|1986-12-01|ANALOGY PROCEDURE FOR THE PREPARATION OF IMIDAZOQUINOLINES OR SALTS THEREOF

---

JPH062744B2|1994-01-12|3-Aminocarbonylmethoxy-5-phenylpyrazole compound, process for producing the same, and drug having antiarrhythmic effect containing the same

---

US4668688A|1987-05-26|N-substituted isoquinoline derivatives and pharmaceutical compositions containing them

---

IL116384A|1996-10-16|Ylidene compounds and their preparation

---

EP0635002A1|1995-01-25|Novel perhydroisoindole derivatives and preparation thereof

---

US4247555A|1981-01-27|4,9-Dihydro-9-oxo-N-1H-tetrazol-5-yl-pyrazolo[5,1-b]-quinazoline-2-carboxamides and antiallergic compositions and methods using them

---

US4775673A|1988-10-04|Substituted acylpiperazinoquinazolines and pharmaceutical compositions containing same

---

EP0389425B1|1995-04-26|Benzotiopyranyl amines

---

US4232031A|1980-11-04|Process for preparation of piperidyl-indoles

---

GB2171997A|1986-09-10|4-Amino-6,7-dimethoxy-2-Piperazin-1-ylquinazoline derivatives

---

US4853406A|1989-08-01|Polyhydrobenzi[c,d]indolesulphonamides

---

JP2848165B2|1999-01-20|Method for producing asymmetric dihydropyridine derivatives

---

US4198509A|1980-04-15|Mercaptoacylpiperazine carboxylic acid compounds

同族专利:

---

公开号 | 公开日

---

JPH0780871B2|1995-08-30|

---

CA1295613C|1992-02-11|

---

IL80560D0|1987-02-27|

---

EP0222191A1|1987-05-20|

---

ZA868531B|1987-07-29|

---

DK536486D0|1986-11-10|

---

NO864474L|1987-05-12|

---

FI864555A|1987-05-12|

---

FI88504C|1993-05-25|

---

HUT42084A|1987-06-29|

---

DE3677322D1|1991-03-07|

---

AU593593B2|1990-02-15|

---

DD263058A5|1988-12-21|

---

AU6498286A|1987-05-14|

---

NO864474D0|1986-11-10|

---

IE59056B1|1993-12-15|

---

HU196793B|1989-01-30|

---

GR3001412T3|1992-09-25|

---

DK536486A|1987-05-12|

---

IE862960L|1987-05-11|

---

US4841047A|1989-06-20|

---

FI864555A0|1986-11-10|

---

CN86107627A|1987-07-15|

---

PT83713A|1986-12-01|

---

FI88504B|1993-02-15|

---

EP0222191B1|1991-01-30|

---

JPS62114987A|1987-05-26|

---

ES2031813T3|1993-01-01|

---

DK172076B1|1997-10-13|

---

AT60598T|1991-02-15|

---

PT83713B|1989-06-30|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

US3017411A|1962-01-16|New substituted phthalazones and proc- |

---

DE2114884A1|1971-03-27|1972-10-12|Cassella Farbwerke Mainkur Ag, 6000 Frankfurt|Basically substituted derivatives of 1 -phthalazinone|

---

US3813384A|1972-01-17|1974-05-28|Asta Werke Ag Chem Fab|Basically substituted benzyl phthalazone derivatives,acid salts thereof and process for the production thereof|

---

DE3530793A1|1984-09-14|1986-03-27|Asta-Werke Ag Chemische Fabrik, 4800 Bielefeld|Substituted benzylphthalazinone derivatives|

---

DE3575135D1|1984-09-14|1990-02-08|Asta Pharma Ag|SUBSTITUTED BENZYLPHTHALAZINONE DERIVATIVES.|AU609210B2|1987-11-13|1991-04-26|Viatris Gmbh & Co. Kg|Azelastine embonate, processes for its preparation and pharmaceutical formulations which contain azelastine embonate as active substance|

---

EP0322153A3|1987-12-21|1990-08-16|Pfizer Inc.|Heterocyclic oxophtalazinyl acetic acids|

---

FR2643373B1|1989-01-10|1993-12-31|Adir Cie|NOVEL BISARYLALCENE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM|

---

DE4013696A1|1989-05-05|1990-11-08|Asta Pharma Ag|New azelastin salts|

---

JPH04198180A|1990-11-28|1992-07-17|Eezai Kagaku Kk|Production of benzylphthalazone derivative|

---

DE4207234A1|1992-03-07|1993-09-09|Asta Medica Ag|NEW AMINOCARBONIC ACID DERIVATIVES WITH ANTIALLERGIC / ANTIASTHMIC EFFECT AND METHOD FOR THE PRODUCTION THEREOF|

---

EP0561166A1|1992-03-17|1993-09-22|ASTA Medica Aktiengesellschaft|Aerosol compositions containing compound D-18024 and its analogs|

---

CZ199593A3|1992-10-02|1994-04-13|Asta Medica Ag|Phthalazinone derivatives exhibiting anti-arrhythmic and analgesic activity and eliminating resistance to a plurality of medicaments |

---

US7151102B2|2000-10-30|2006-12-19|Kudos Pharmaceuticals Limited|Phthalazinone derivatives|

---

DE60335359D1|2002-04-30|2011-01-27|Kudos Pharm Ltd|phthalazinone|

---

US7449464B2|2003-03-12|2008-11-11|Kudos Pharmaceuticals Limited|Phthalazinone derivatives|

---

GB0305681D0|2003-03-12|2003-04-16|Kudos Pharm Ltd|Phthalazinone derivatives|

---

GB0419072D0|2004-08-26|2004-09-29|Kudos Pharm Ltd|Phthalazinone derivatives|

---

RS58377B1|2004-11-24|2019-04-30|Meda Pharmaceuticals Inc|Compositions comprising azelastine and methods of use thereof|

---

US20070020330A1|2004-11-24|2007-01-25|Medpointe Healthcare Inc.|Compositions comprising azelastine and methods of use thereof|

---

US8758816B2|2004-11-24|2014-06-24|Meda Pharmaceuticals Inc.|Compositions comprising azelastine and methods of use thereof|

---

GB0428111D0|2004-12-22|2005-01-26|Kudos Pharm Ltd|Pthalazinone derivatives|

---

GB0521373D0|2005-10-20|2005-11-30|Kudos Pharm Ltd|Pthalazinone derivatives|

---

DE602007010118D1|2006-04-20|2010-12-09|Glaxo Group Ltd|2-SUBSTITUTED 4-BENZYLPHTHALAZINE DERIVATIVES AS HISTAMINE H1 AND H3 ANTAGONISTS|

---

CN101500997A|2006-06-15|2009-08-05|库多斯药物有限公司|PARP inhibitors|

---

US20090281086A1|2006-06-15|2009-11-12|Kudos Pharmaceuticals Limited|2 -oxyheteroarylamide derivatives as parp inhibitors|

---

JP2009541217A|2006-06-15|2009-11-26|クドスファーマシューティカルズリミテッド|2-Oxybenzamide derivatives as PARP inhibitors|

---

UY30639A1|2006-10-17|2008-05-31|Kudos Pharm Ltd|SUBSTITUTED DERIVATIVES OF 2H-FTALAZIN-1-ONA, ITS CRYSTAL FORMS, PREPARATION PROCESS AND APPLICATIONS|

---

US20100184770A1|2006-12-20|2010-07-22|Glaxo Group Limited|Compounds|

---

US20080280910A1|2007-03-22|2008-11-13|Keith Allan Menear|Phthalazinone derivatives|

---

TW200900396A|2007-04-10|2009-01-01|Kudos Pharm Ltd|Phthalazinone derivatives|

---

US20090023727A1|2007-07-05|2009-01-22|Muhammad Hashim Javaid|Phthalazinone derivatives|

---

KR20100059950A|2007-09-14|2010-06-04|아스트라제네카 아베|Phthalazinone derivatives|

---

WO2009047336A1|2007-10-11|2009-04-16|Glaxo Group Limited|Phthalazine and pyrido [3,4-d] pyridaz ine compounds as h1 receptor antagonists|

---

ES2530695T3|2007-10-17|2015-03-04|Kudos Pharm Ltd|4- [3--4-fluoro-benzyl] -2H-phthalazin-1-one|

---

AR070221A1|2008-01-23|2010-03-25|Astrazeneca Ab|DERIVATIVES OF FTALAZINONA POLYMERASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USES OF THE SAME TO PREVENT AND / OR TREAT CANCERIGENE TUMORS, ISCHEMICAL INJURIES AND OTHER ASSOCIATED DISEASES.|

---

WO2010041051A1|2008-10-07|2010-04-15|Astrazeneca Uk Limited|Pharmaceutical formulation 514|

---

TW201114756A|2009-07-15|2011-05-01|Astrazeneca Ab|Phthalazinone compound|

法律状态:

优先权:

---

申请号 | 申请日 | 专利标题

---

DE3539873|1985-11-11|

---